Official Title
Compassionate Use Program Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)
Brief Summary

The objective of this program is to allow treating physicians to supply/continue to supply Certolizumab Pegol (CIMZIA®, CZP) to adults suffering from Crohn's Disease (CD), and who are considered not suitable for treatment, intolerant, have medical contraindications or had insufficient response with an authorized conventional therapy, including other authorized biologics.

Individual Patients
Crohn's Disease

Drug: Certolizumab Pegol
Other Name: Cimzia

Eligibility Criteria

Inclusion Criteria:

- Patient comes from ending open label studies such as WELCOME -C87046, COSPAR - C87065,
MUSIC - C87043, PRECISE 3 - C87033, PRECISE 4 - C87034 and C87088

Exclusion Criteria: - Patient has been treated with any experimental biological or non biological therapy other than Certolizumab Pegol (CZP) within 5 plasma half-lifes* - Has been treated with an approved biological, namely infliximab within the last 8 weeks, and adalimumab within the last 2 weeks* - Known hypersensitivity to CZP or any of its excipients - Current or recent history of severe, progressive, uncontrolled renal, hepatic, haematological, gastrointestinal (other than Crohn's disease), endocrine, pulmonary, cardiac, neurological, or cerebral disease - Serious or life threatening infection within the last 6 months, any signs of current or recent infection - Active or latent tuberculosis (TB): if one or more of the 3 criteria is positive for evidence of TB infection*: 1. A medical history of or a recent (< 6 months) active tuberculosis (TB) 2. A recent (

Eligibility Gender
Eligibility Age
Minimum: 18 Years

UCB Cares
+1 844 599 2273

UCB Cares
Study Director
001 844 599 2273 (UCB)

UCB Biopharma S.P.R.L.
NCT Number
MeSH Terms
Crohn Disease
Certolizumab Pegol